Molecular structure of Sitagliptin, CAS Number: 486460-32-6
Sitagliptin (CAS 486460-32-6)
See product citations (10)
Alternate Names:
Januvia; Xelevia; Sitagliptan; Janumet
Application:
Sitagliptin is a DPP-4 inhibitor
CAS Number:
486460-32-6
Molecular Weight:
407.31
Molecular Formula:
C16H15F6N5O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sitagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor. This small molecule operates by enhancing the levels of active incretin hormones within the body, thereby facilitating the regulation of glucose levels. The mechanism behind Sitagliptin′s effectiveness lies in its ability to impede the action of dipeptidyl peptidase-4, the enzyme responsible for the degradation of incretin hormones. By inhibiting this enzyme, Sitagliptin increases the concentration of active incretin hormones, such as GLP-1 and GIP.
Sitagliptin (CAS 486460-32-6) References
- Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | Miller, S. and St Onge, EL. 2006. Ann Pharmacother. 40: 1336-43. PMID: 16868220
- Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. | Gallwitz, B. 2007. Drugs Today (Barc). 43: 13-25. PMID: 17315049
- Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. | Zerilli, T. and Pyon, EY. 2007. Clin Ther. 29: 2614-34. PMID: 18201579
- Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. | Pham, DQ., et al. 2008. Am J Health Syst Pharm. 65: 521-31. PMID: 18319497
- Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. | Dhillon, S. 2010. Drugs. 70: 489-512. PMID: 20205490
- Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. | Chwieduk, CM. 2011. Drugs. 71: 349-61. PMID: 21319871
- Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics. | Ramadan, WH. and Kabbara, WK. 2015. Vasc Health Risk Manag. 11: 125-32. PMID: 25709467
- Sitagliptin for Type 2 diabetes: a 2015 update. | Lee, M. and Rhee, MK. 2015. Expert Rev Cardiovasc Ther. 13: 597-610. PMID: 26000559
- Cardiovascular effects of sitagliptin - An anti-diabetes medicine. | Zhou, Y., et al. 2018. Clin Exp Pharmacol Physiol. 45: 628-635. PMID: 29679391
- Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. | Zeng, DK., et al. 2019. Biosci Rep. 39: PMID: 31262972
- Efficacy and Safety of Sitagliptin in the Treatment of COVID-19. | Mikhael, EM., et al. 2022. J Pharm Pract. 8971900221102119. PMID: 35581701
- Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder. | Huang, S., et al. 2022. Oxid Med Cell Longev. 2022: 2586305. PMID: 35620578
Inhibitor of:
AL-1, Amylase 2A, Amylase 2B, CD26, CDKAL1, DPP10, DPPA4, GIP, GPR119, Insulin, NAALAD2, Olr1591, Olr255, and Pancreatic Icosapeptide.Activator of:
APNG, CPA4, GLP1, IGRP, Insulin II, PCBD1, and TBC1D4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sitagliptin, 25 mg | sc-482298 | 25 mg | $213.00 | |||
Sitagliptin, 100 mg | sc-482298A | 100 mg | $473.00 | |||
Sitagliptin, 1 g | sc-482298B | 1 g | $733.00 |